Login to Your Account

Onlookers ponder Biocryst's likely place in HAE as kallikrein inhibitor advances

By Randy Osborne
Staff Writer

Monday, March 20, 2017

As Biocryst Pharmaceuticals Inc. prepared to close its $45 million financing round last week, work continued with BCX7353 and second-generation compounds for hereditary angioedema (HAE). So did speculation about the oral, second-generation kallikrein inhibitor's chances in the crowded HAE space, as company watchers mulled interim outcomes unveiled in late February from APeX-1, a phase II dose ranging trial.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription